ABEO Abeona Therapeutics Inc.

-0.05  -1%
Previous Close 5.95
Open 5.90
Price To book 2.42
Market Cap 237.50M
Shares 40,255,000
Volume 67,193
Short Ratio 16.42
Av. Daily Volume 238,374

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1/2 updated data presented at Society for Investigative Dermatology (SID) April 28, 2017.
Recessive dystrophic epidermolysis bullosa (RDEB)
Phase 2 enrollment commenced September 2016.
Recessive dystrophic epidermolysis bullosa (RDEB)
Phase 1/2 updated data released May 12, 2017.
Sanfilippo syndrome type A (MPS IIIA)

Latest News

  1. Abeona Therapeutics to Present at Multiple Upcoming Conferences
  2. Abeona Therapeutics reports 1Q loss
  3. Abeona Therapeutics Reports First Quarter 2017 Financial Results and Recent Business Highlights
  4. Abeona Therapeutics Announces Top-Line Data for ABO-102 Phase 1/2 MPS IIIA Gene Therapy Trial at ASGCT
  5. Abeona Therapeutics Receives Regulatory Approval to Initiate Clinical Trial in Australia with ABO-102 Gene Therapy For Patients with MPS IIIA
  6. Abeona Therapeutics Announces Gene Therapy Clinical Trial and Preclinical Program Presentations at ASGCT 20th Annual Meeting
  7. Abeona Therapeutics Provides Update on EB-101 Gene Therapy for Severe Form of Epidermolysis Bullosa from the Society for Investigative Dermatology Conference
  8. ETFs with exposure to Abeona Therapeutics, Inc. : April 25, 2017
  9. Abeona Therapeutics Announces EB-101 Clinical Update to be Presented at the Society for Investigative Dermatology Annual Meeting
  10. Abeona to Present At Multiple Upcoming Conferences
  11. Edited Transcript of ABEO earnings conference call or presentation 10-Apr-17 2:00pm GMT
  12. Abeona Announces Rare Disease Gene Therapy Symposium with the New York Academy of Sciences
  13. Abeona Therapeutics, Inc. :ABEO-US: Earnings Analysis: Q4, 2016 By the Numbers : April 3, 2017
  14. Abeona Therapeutics Reports Q4 2016 Financial Results and Business Highlights
  15. Abeona Therapeutics to Present at Multiple Upcoming Investor Conferences
  16. Abeona Therapeutics Receives Orphan Drug Designation in the European Union for EB-101 Gene Therapy Clinical Trial for Epidermolysis Bullosa
  17. Abeona Therapeutics To Present At The Cowen and Company 37th Annual Health Care Conference
  18. Abeona Therapeutics to Present at Maxim Group LLC Biotech Investor & Partnering Conference in Shanghai
  19. In Honor of International Rare Disease Day, Abeona Therapeutics (Nasdaq: ABEO) Set to Ring the Nasdaq Stock Market Closing Bell